Selected Publications
Ye J, Pan H, Reaman G, Roychoudhury S, Lu C, Renfro LA, Ji Y, Liu R, Yuan Y, and Zhang W. Considerations on design and analysis of external control in pediatric oncology. Medical Research Archives, 2024. doi:10.18103/mra.v12i1.5088.
Karol SE, Pan H, Yinmei Z, Rubnitz JE, Bhakta N, Jeha S, Relling MV, Crews KR, Panetta JC, Morin C, Cheng C, Pui C-H, Inaba H, and McCarville MB. Zegocractin to reduce the severity of asparaginase associated pancreatitis in children with acute lymphoblastic leukemia: results of the phase 1 portion of the Crspa study. Blood, 2023. doi:10.1182/blood-2023-188357.
Pan H, Yuan Y. Bayesian Adaptive Design for Immunotherapy and Targeted Therapy. Springer Press. 2023.
Semko JH, Longoria J, Porter J, Potter B, Bhatia S, Pan H, Hankins JS, Heitzer AM. Examining the influence of pain and fatigue on neurocognitive functioning in adolescents and young adults with sickle cell disease. Pediatric Blood & Cancer 2023. doi:10.1002/pbc.30621
Li C, Huang P, Pan H. Introduction to Bayesian Group Sequential Design. Clinical Trials - Recent Advances, 2022. doi:10.5772/intechopen.108852
Zhong C, Miao H, Pan H*. A Bayesian two-stage group sequential scheme for ordinal endpoints. Journal of the Royal Statistical Society Series C: Applied Statistics, 2023. doi:10.1093/jrsssc/qlad026. *Corresponding Author
Ye J, Zhang V, Strimenopoulou F, Zhao Y, Pan H, Shabbout M, and Gamalo M. Recent Use of Pediatric Extrapolation in Pediatric Drug Development in US. Journal of Biopharmaceutical Statistics, 2023. doi:10.1080/10543406.2023.2170407.
Pan H, Yuan X, Ye J. An optimal two-period multiarm platform design with new experimental arms added during the trial. The New England Journal of Statistics in Data Science 2022. doi:10.51387/22-NEJSDS15.
Heitzer AM, Schreiber JE, Yuan X, Wang F, Pan H, Graff JC, Murphy L, Rupff R, Russell K, Wang W, Estepp JH, Hankins JS, Porter JS, and Jacola LM. Working memory and school readiness in preschool children with sickle cell disease compared to demographically matched controls. British Journal of Haematology 2022. doi:10.1111/bjh.18507.
Merchant TE, Dangda S, Hoehn ME, Wu S, Li Y, Wang F, Pan H, Boop FA, Jurbergs N, and Conklin HM. Pediatric Craniopharyngioma: The Impact of Visual Deficits and Hormone Deficiencies on Long-term Cognitive Outcomes after Conformal Photon Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. 2022.
Li C, Sun H, Cheng C, Tang L, and Pan H*. A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs. Contemporary Clinical Trials Communications, 100990, 2022. *Corresponding Author.
Pan H*, Mu R, Hsu CW, and Zhou S. An R package UnifiedDoseFinding for continuous and ordinal outcomes in Phase I dose-finding trials. Communications for Statistical Applications and Methods 29(4): 421-439, 2022. *Corresponding author.
Su X, Li Y, Muller P, Hsu C-W, Pan H, Do K-A. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. Pharmaceutical Statistics 2022. doi:10.1002/pst.2249
Wu J, Pan H*, Hsu C-W. Two-stage screened designs for randomized phase II trials with time-to-event endpoints. Biometrical Journal. doi:10.1002/bimj.202100305. 2022. *Corresponding author.
Song N, Sim J, Dong Q, Zheng Y, Hou L, Li Z, Hsu C, Pan H, Mulder H, Easton J, Walker E, Neale G, Wilson CL, Ness KK, Krull KR, Srivastava DK, Yasui Y, Zhang J, Hudson MM, Robison LL, Huang I, Wang Z. Blood DNA methylation signatures are associated with social determinants of health among survivors of childhood cancer. Epigenetics 1-15, 2022.
Young M, Delaney A, Jurbergs N, Pan H, Wang F, Boop FA, Merchant TE. Radiotherapy alone for pediatric patients with craniopharyngioma. J Neurooncol 156(1):195-204, 2022.
Sharp K, Tillery R, Long A, Wang F, Pan H, Phipps S. Trajectories of resilience and posttraumatic stress in childhood cancer: consistency of child and parent outcomes. Health Psychol 41(4):256-267, 2022.
LaRosa KN, MacArthur E, Wang F, Zhang H, Pan, H, Brigden J, Pappo A, W. Wilson MW, and Crabtree VM. Light Therapy for QoL/Depression in AYA With Cancer: A Randomized Trial. Journal of Pediatric Psychology 2021.
Ghafoor S, Fan K, Williams S, Brown A, Bowman S, Pettit KL, Pan H, Gorantla S, et al. Beginning Restorative Activities Very Early: Implementation of an Early Mobility Initiative in a Pediatric Onco-Critical Care Unit. Frontiers in Oncology 11: 407, 2021.
Mu R, Pan H*, and Xu G. A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. Statistics in Medicine 40 (2): 382-402, 2021. *Corresponding Author
Laplant J, Wilson MW, Wang F, Pan H, King BA, and Brennan R. Intravitreal Chemotherapy Eligibility and Ocular Survival for Advanced Retinoblastoma. Investigative Ophthalmology & Visual Science 62 (8): 2851-2851, 2021.
Khan RB, Bano M, Wang F, Haitao, H, Christensen A, Smith J, Simmons A, and Sadighi ZS. Height, weight, and cardiovascular effects of stimulants on children with brain tumors. Pediatric Blood & Cancer 68 (1): e28740, 2021.
DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Poussaint TY, Baxter PA, et al. "A Phase I and surgical study of ribociclib and everolimus in children with recurrent or refractory malignant brain tumors: A Pediatric Brain Tumor Consortium Study." Clinical Cancer Research, 2021.
Mu R, Hu Z, Xu G, Pan H*. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials. BMC Medical Research Methodology 21(1):1-12, 2021. *Corresponding author
Mu R, Xu G, Liu G, Pan H*. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. Contemporary Clinical Trials Jul 22;108:106504, 2021. *Corresponding author
Wu J, Pan H*, Hsu C-W. Bayesian single‐arm phase II trial designs with time‐to‐event endpoints. Pharmaceutical Statistics 2021. PMID: 34085764 *Corresponding author
Li C, Pan H*. A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries. PLoS One. Aug 27;15(8):e0237254, 2020. doi: 10.1371/journal.pone.0237254. eCollection 2020.
Mu R, Pan H, Xu G. A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. Stat Med Oct 22, 2020. doi: 10.1002/sim.8780. Corresponding author
Khan RB, Bano M, Wang F, Pan H, Christensen A, Smith J, Simmons A, Sadighi ZS. Height, weight, and cardiovascular effects of stimulants on children with brain tumors. Pediatr Blood Cancer Oct 13;e28740, 2020. doi: 10.1002/pbc.28740
Oshiro Y, Mizumoto M, Pan H, Kaste SC, Gajjar A, Merchant TE.. Spinal changes after craniospinal irradiation in pediatric patients. Pediatr Blood Cancer Dec;67(12):e28728, 2020. doi: 10.1002/pbc.28728
Qin N, Li Z, Song N, Wilson CL, Easton J, Mulder H, Plyler E, Neale G, Walker E, Zhou X, Pan H, Hudson MM, Yasui Y, Robison LL, Zhang J, Ness KK, Wang Z. Epigenetic Age Acceleration and Chronic Health Conditions among Adult Survivors of Childhood Cancer. J Natl Cancer Inst Sep 24;djaa147, 2020. doi: 10.1093/jnci/djaa147
Mizumoto M, Oshiro Y, Pan H, Wang F, Kaste SC, Gajjar A, Chemaitilly W, Merchant TE. Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors. Pediatr Blood Cancer 2020 Jul 26;e28617, 2020. doi: 10.1002/pbc.28617
Wallace D, Taylor DR, Pan H, Hwang S,Lucas JT Jr, Klimo Jr P, Upadhyaya SA, Boop FA. Treatment-related calvarial lesions in pediatric brain tumor survivors. Pediatr Blood Cancer Jun;67(6):e28189, 2020. doi: 10.1002/pbc.28189.
Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharm Stat Apr 5, 2020. doi: 10.1002/pst.2013. [Epub ahead of print]
Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemp Clin Trials Mar 7;92:105972, 2020. doi: 10.1016/j.cct.2020.105972. [Epub ahead of print]
Xu H, Pan H, Wang Y, Zhang J. Expanded study on the risk of lymphovascular space invasion and lymph node metastasis of endocervical adenocarcinoma using Pattern Classification: a single-centre analysis of 213 cases. Pathology 51(6):570-78, 2019. doi.org/10.1016/j.pathol.2019.04.008 (Co-First author)
Wu K, Pan H, Li C, Zhao Q, Wang L, Xia J. An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment. PLoS One Dec 6;13(12):e0208354, 2018. doi: 10.1371/journal.pone.0208354. eCollection 2018. (Co-First Author)
Lavado A, Park JY, Paré J, Finkelstein D, Pan H, Xu B, Fan Y, Kumar RP, Neale G, Kwak YD, McKinnon PJ, Johnson RL, Cao X. The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number. Developmental Cell Dec 3;47:1-16, 2018. doi: 10.1016/j.devcel.2018.09.021
Kejian W, Qingbo Z, Chanjun L, Ling W, Chen L, Pan H*, Jielai X*. Some Statistical Considerations in Analytical similarity Assessment of Biosimilar Studies. Chinese Journal of Health Statistics 35(3):344-348, 2018. (*Corresponding author) (in Chinese)
Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine March 2018. DOI: 10.1002/sim.7674 PMID: 29682777
Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. BMC Medical Research Methodology March;18:32, 2018. https://doi.org/10.1186/s12874-018-0473-2
Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Stat Med Jan 30;36(2):266-279, 2017. doi: 10.1002/sim.6941. Epub 2016 Mar 16. PubMed PMID: 26991076; PubMed Central PMCID: PMC5026535.
Zhao L, Pan H. Radiotherapy alone or concurrent chemoradaition for esophageal squamous cell carcinoma in elderly patients. Journal of Cancer Research and Clinical Oncology 2017.
Zhao L, Xu M, Jiang W, Pan H, Zang J, Luo S, Wang J, Zhou Y, Shi M. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. Oncotarget Jan 24;8(4):6763-6774, 2017.
Pan H, Yuan Y, Xia J. A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2016.
Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine 35(20):3497-508, 2016.
Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine 34(10):1681-94, 2015.
Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. PLoS ONE 9(5), 2014.
Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. Spinal Changes of a Newly Isolated Neuropeptide Endomorphin-2 Concomitant with Vincristine-Induced Allodynia. PLoS ONE 9(2):e89583, 2014.
Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. The effects of different hyperbaric oxygen manipulations in rats after traumatic brain injury. Neuroscience Letters 563:38-43, 2014.
Pan H, Xie F, Liu P, Xia J, Ji Y. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials 11(1):49-59, 2014.
Pan H, Huang P, Wang Z, Wang L, Li C, Xia J. A Novel Bayesian Seamless Phase I/II Design. PLoS ONE 8(9), 2013.
Pan H, Ji Y, Chen Z, Li C, Xia J. The Choice Of Phase I Bayesian Adaptive Designs In China. International Journal of Drug Discovery 5(1):185-90, 2013.
Pan H, Li C, Wang L, Jiang Z, Xia J. A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies. Communications in Statistics - Simulation and Computation 43(2):254-68, 2013.
Last update: March 2024